New hope in glioblastoma treatment: The defense mechanism of the deadly brain tumor is solved

In an international study, an important finding was reached regarding the defense shield of glioblastoma, a deadly brain tumor that is highly resistant to chemotherapy and radiation.

Ohio State University Cancer Center researchers have identified a biological target that weakens cancer cells by examining the mechanisms that ensure tumor survival.

In experiments carried out in laboratory and animal models, the 'SET' protein, which suppresses the enzyme called 'PP2A', which controls the growth of cancer cells and their recovery after treatment, was examined. Researchers found that blocking this protein prevented tumor formation and left the remaining cancer cells extremely vulnerable to radiation therapy.

'IT CAN DOUBLE THE EFFECT OF RADIOTHERAPY AND CHEMOTHERAPY'

Author of the study and radiation oncology specialist Dr. Arnab Chakravarti said in his statement on the subject, "Glioblastoma is one of the most difficult cancers to treat due to its ability to adapt and survive. Our findings show that reactivating the 'PP2A' enzyme breaks the resistance mechanism of cancer cells. This step can make existing radiotherapy and chemotherapy much more effective on patients."

Experts stated that the method in question is still in the pre-clinical stage and safety and effectiveness tests on humans will be carried out. The research team noted that the survival of glioblastoma patients could be extended by developing new targeted drug combinations.